Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process

Author(s): Kelly E. Caudle, Teri E. Klein, James M. Hoffman, Daniel J. Muller, Michelle Whirl-Carrillo, Li Gong, Ellen M. McDonagh, Katrin Sangkuhl, Caroline F. Thorn, Matthias Schwab, Jose A.G. Agundez, Robert R. Freimuth, Vojtech Huser, Ming Ta Michael Lee, Otito F. Iwuchukwu, Kristine R. Crews, Stuart A. Scott, Mia Wadelius, Jesse J. Swen, Rachel F. Tyndale, C. Michael Stein, Dan Roden, Mary V. Relling, Marc S. Williams and Samuel G. JohnsonPages...

Read More

A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?

Author(s): Lorena Baietto, Silvia Corcione, Giovanni Pacini, Giovanni Di Perri, Antonio D’Avolio and Francesco Giuseppe De RosaPages 581-598 (18) Abstract: Drug bioavailability may vary greatly amongst individuals, affecting both efficacy and toxicity: in humans, genetic variations account for a relevant proportion of such variability. In the last decade the use of pharmacogenetics in clinical practice, as a tool to individualize treatment,...

Read More

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide

Author(s): Mario Cozzolino, Felix Funk, Viatcheslav Rakov, Olivier Phan and Isaac TeitelbaumPages 953-965 (13) Abstract: Sucroferric oxyhydroxide (VELPHORO®) is a polynuclear iron-based phosphate binder recently approved for the treatment of hyperphosphataemia in patients with chronic kidney disease (CKD). As a number of the available phosphate binders do not provide the optimal combination of good efficacy, adequate tolerability and low pill...

Read More

Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines

Author(s): Derek W. Edwardson, Rashmi Narendrula, Simon Chewchuk, Kyle Mispel-Beyer, Jonathan P.J. Mapletoft and Amadeo M. ParissentiPages 412-426 (15) Abstract: Many clinical studies involving anti-tumor agents neglect to consider how these agents are metabolized within the host and whether the creation of specific metabolites alters drug therapeutic properties or toxic side effects. However, this is not the case for the anthracycline class...

Read More

Digestive Enzyme Supplementation in Gastrointestinal Diseases

Author(s): Gianluca Ianiro, Silvia Pecere, Valentina Giorgio, Antonio Gasbarrini and Giovanni CammarotaPages 187-193 (7) Abstract: Background: Digestive enzymes are able to break down proteins and carbohydrates and lipids, and their supplementation may play a role in the management of digestive disorders, from lactose intolerance to cystic fibrosis. To date, several formulations of digestive enzymes are available on the market, being different...

Read More